• 1. A 47-year-old woman with AChR-Ab+ gMG has been on prednisone 20 mg/day for 3 years plus monthly IVIg. Her MG-ADL is 4, and she has gained weight and has insomnia. She is asking about B-cell–directed options. Which statement is best supported by randomized trial evidence?*
  • 2. Which statement best describes telitacicept?*
  • 3. A 38-year-old woman with MuSK-Ab+ gMG responded to rituximab in the past. She now has recurring dysphagia and dysarthria, with an MG-ADL of 7. Which plan is most appropriate?*
  • Which of the following best describes your title?*

  • Please rate the extent to which this activity met the following objectives:

  • Learning Objectives
    Rows
  • Do you feel this activity was fair balanced and free of commercial bias?
  • This educational activity will result in a change in my role as a healthcare team member.
  • This educational activity will result in a change in my practice behavior.
  • Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:
  • Attestation to time spent on activity: AcademicCME designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.

  • AcademicCME thanks you for your participation in this activity. All information provided improves the scope and purpose of our programs.

  • Should be Empty: